Hemminki A - Search Results

1

Oncolytic adenovirus based on serotype 3.

Hemminki O, Bauerschmitz G, Hemmi S, Lavilla-Alonso S, Diaconu I, Guse K, Koski A, Desmond RA, Lappalainen M, Kanerva A, Cerullo V, Pesonen S, Hemminki A. Hemminki O, et al. Among authors: hemminki a. Cancer Gene Ther. 2011 Apr;18(4):288-96. doi: 10.1038/cgt.2010.79. Epub 2010 Dec 24. Cancer Gene Ther. 2011. PMID: 21183947 Free article.

2

Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma.

Mahasreshti PJ, Navarro JG, Kataram M, Wang MH, Carey D, Siegal GP, Barnes MN, Nettelbeck DM, Alvarez RD, Hemminki A, Curiel DT. Mahasreshti PJ, et al. Among authors: hemminki a. Clin Cancer Res. 2001 Jul;7(7):2057-66. Clin Cancer Res. 2001. PMID: 11448924

3

Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule.

Hemminki A, Dmitriev I, Liu B, Desmond RA, Alemany R, Curiel DT. Hemminki A, et al. Cancer Res. 2001 Sep 1;61(17):6377-81. Cancer Res. 2001. PMID: 11522629

4

An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression.

Hemminki A, Belousova N, Zinn KR, Liu B, Wang M, Chaudhuri TR, Rogers BE, Buchsbaum DJ, Siegal GP, Barnes MN, Gomez-Navarro J, Curiel DT, Alvarez RD. Hemminki A, et al. Mol Ther. 2001 Sep;4(3):223-31. doi: 10.1006/mthe.2001.0446. Mol Ther. 2001. PMID: 11545613 Free article.

5

Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells.

Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, Barker SD, Straughn M, Barnes MN, Alvarez RD, Hemminki A, Curiel DT. Kanerva A, et al. Among authors: hemminki a. Clin Cancer Res. 2002 Jan;8(1):275-80. Clin Cancer Res. 2002. PMID: 11801569

6

Treatment of ovarian cancer with a tropism modified oncolytic adenovirus.

Bauerschmitz GJ, Lam JT, Kanerva A, Suzuki K, Nettelbeck DM, Dmitriev I, Krasnykh V, Mikheeva GV, Barnes MN, Alvarez RD, Dall P, Alemany R, Curiel DT, Hemminki A. Bauerschmitz GJ, et al. Among authors: hemminki a. Cancer Res. 2002 Mar 1;62(5):1266-70. Cancer Res. 2002. PMID: 11888888

7

The flt-1 promoter for transcriptional targeting of teratocarcinoma.

Bauerschmitz GJ, Nettelbeck DM, Kanerva A, Baker AH, Hemminki A, Reynolds PN, Curiel DT. Bauerschmitz GJ, et al. Among authors: hemminki a. Cancer Res. 2002 Mar 1;62(5):1271-4. Cancer Res. 2002. PMID: 11888889

8

Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv.

Arafat WO, Gómez-Navarro J, Buchsbaum DJ, Xiang J, Wang M, Casado E, Barker SD, Mahasreshti PJ, Haisma HJ, Barnes MN, Siegal GP, Alvarez RD, Hemminki A, Nettelbeck DM, Curiel DT. Arafat WO, et al. Among authors: hemminki a. Gene Ther. 2002 Feb;9(4):256-62. doi: 10.1038/sj.gt.3301639. Gene Ther. 2002. PMID: 11896464

9

Adenoviruses in oncology: a viable option?

Hemminki A, Alvarez RD. Hemminki A, et al. BioDrugs. 2002;16(2):77-87. doi: 10.2165/00063030-200216020-00001. BioDrugs. 2002. PMID: 11985481 Review.

10

In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus.

Hemminki A, Zinn KR, Liu B, Chaudhuri TR, Desmond RA, Rogers BE, Barnes MN, Alvarez RD, Curiel DT. Hemminki A, et al. J Natl Cancer Inst. 2002 May 15;94(10):741-9. doi: 10.1093/jnci/94.10.741. J Natl Cancer Inst. 2002. PMID: 12011224

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

348 results

Search Page

Filters